HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $4.5 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on Nuvation Bio (NYSE:NUVB) and maintained a price target of $4.5.
August 21, 2023 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nuvation Bio's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $4.5.
The reiteration of a 'Buy' rating by a reputable analyst like Robert Burns from HC Wainwright & Co. is a positive signal for Nuvation Bio. The maintained price target of $4.5 also indicates confidence in the company's stock performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100